Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Market Wrap: Stocks and metals dip as Trump-Xi summit fails to break Iran deadlock ๐ (15.05.2026)
Daily Summary: Market euphoria shows no signs of letting up ๐
Will OpenAI launch a legal battle against Appleโ๏ฟฝ
US OPEN: Cisco shares surge; markets open higher โฐ